Analyst firms · BTIG · GMED
BTIG GMED price target and rating history
Globus Medical Inc. (GMED) · Health Care
BTIG rates Globus Medical Inc. (GMED) Neutral with a $60 price target, as of its latest action on May 27, 2025. It has published 3 rating actions on GMED since February 2023, including 1 upgrade and 2 downgrades. Across 4 firms with a GMED price target in the last 12 months, the median target is $96.
- Current rating
- Neutral
- Price target
- $60
- Median target, all firms
- $96
- Actions on GMED
- 3
Every BTIG rating on GMED
- May 27, 2025DowngradeBTIG downgrades to Neutral from Buy
- Mar 18, 2024
- Feb 10, 2023DowngradeBTIG downgrades to Neutral from Buy
How other firms rate GMED
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BMO Capital Markets | Market Perform | $78 | Nov 6, 2026 |
| UBS | Neutral | $82 | Jul 28, 2026 |
| Needham | Buy | $112 | Jan 30, 2026 |
| TD Cowen | Buy | $110 | Jan 27, 2026 |
Questions about BTIG and GMED
- What is BTIG's price target for GMED?
- BTIG's latest stated price target for Globus Medical Inc. (GMED) is $60, from its action on Mar 18, 2024.
- What is BTIG's rating on GMED?
- BTIG rates GMED Neutral, a neutral rating, as of May 27, 2025.
- When did BTIG last change its view on GMED?
- On May 27, 2025, BTIG downgrades to Neutral from Buy.
- How does BTIG's GMED target compare with other analysts?
- Across 4 firms with a GMED price target in the last 12 months, the median target is $96.
More GMED rating histories
All BTIG ratingsGMED news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.